Purpose: The aim of our study was to investigate the prevalence of HF in the CAD population as well as evaluate the compliance of patients towards guideline recommendations.
Methods: We have enrolled 194 consecutive patients who have undergone PCI or CABG for acute myocardial infarction or unstable angina or stable angina between October 2016 and June 2017. Out of this lot we have selected 160 patients who developed heart failure. We have interviewed these patients regarding their medication and lifestyle and have determined their ejection fraction (EF).
Results: Out of the population with heart failure, 76.8% had a preserved EF, while 15.6% had an intermediate EF and 7.5% a reduced EF. However just over half of the patients with intermediate EF (64%) were taking an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB). The most used medication was Ramipril (43.7%), followed by Zofenopril (31.2%), Valsartan (6.2%) and Olmesartan (6.2%). In the group with reduced EF 50% of these patients were on ACE inhibitor or ARB treatment, which included Zofenopril in 66.6% of the cases, Ramipril in 33.3% of the cases and Valsartan in 33.3% of the cases. Moreover, 59% of the entire population with heart failure were not currently taking Spironolactone.
Conclusions: We have noticed that patients at very high cardiovascular risk are poorly controlled regarding their heart failure medication which might be explained by non-adherence to treatment. Awareness should be raised among patients to ensure better compliance regarding medication adherence.